Core Insights - The Hong Kong Innovative Drug ETF (513120) experienced a decline of 1.55% on December 30, with a trading volume of 2.959 billion yuan [1] - The fund's shares increased by 95 million to a total of 19.475 billion shares, with a notable increase of 780 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 23.736 billion yuan [1] Performance Metrics - The performance benchmark for the Hong Kong Innovative Drug ETF is the return rate of the CSI Hong Kong Innovative Drug Index (denominated in RMB) [1] - Managed by Guangfa Fund Management Co., the fund has achieved a return of 21.87% since its inception on July 1, 2022 [1] - Over the past month, the fund has recorded a return of -9.90% [1]
12月30日港股创新药ETF（513120）份额增加9500.00万份
Xin Lang Cai Jing·2025-12-31 01:05